Skip to main content
Premium Trial:

Request an Annual Quote

Dako to Develop Companion Dx for Merck Cancer Drug

NEW YORK (GenomeWeb) – Agilent Technologies' Dako business said today that it will develop a companion diagnostic test for a cancer drug being developed by Merck.

The test will be for the analysis of the potential tumor biomarker PD-L1 as an aid in treating cancer patients with Merck's investigational anti-PD-1 antibody. Financial and other terms of the agreement were not disclosed.

Eric Rubin, VP of oncology for Merck Research Laboratories, said that early findings from its clinical development program have "provided evidence for the potential of PD-L1 tumor expression to aid study enrichment and patient selection in some tumor types."

Neither company specified the particular cancers Merck will target with its drug.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.